Check-Cap (NASDAQ:CHEK) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Check-Cap (NASDAQ:CHEK – Get Rating) from a buy rating to a hold rating in a report released on Thursday morning, Zacks.com reports.

According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “

Separately, Dawson James upgraded shares of Check-Cap from a neutral rating to a buy rating in a research note on Monday, February 7th.

Shares of Check-Cap stock opened at $0.37 on Thursday. The stock has a market capitalization of $36.14 million, a price-to-earnings ratio of -1.78 and a beta of 0.20. The business has a 50-day moving average of $0.41 and a 200 day moving average of $0.63. Check-Cap has a 12 month low of $0.34 and a 12 month high of $1.91.

Check-Cap (NASDAQ:CHEK – Get Rating) last posted its quarterly earnings data on Thursday, April 7th. The medical research company reported ($0.06) EPS for the quarter. Equities research analysts anticipate that Check-Cap will post -0.17 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. lifted its stake in Check-Cap by 242.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 305,991 shares of the medical research company’s stock worth $206,000 after acquiring an additional 216,662 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Check-Cap in the 4th quarter valued at $44,000. GSA Capital Partners LLP purchased a new stake in shares of Check-Cap during the 4th quarter worth $206,000. ARK Investment Management LLC grew its stake in shares of Check-Cap by 6.8% during the fourth quarter. ARK Investment Management LLC now owns 3,257,788 shares of the medical research company’s stock worth $2,198,000 after purchasing an additional 207,260 shares in the last quarter. Finally, Two Sigma Securities LLC purchased a new position in Check-Cap in the third quarter valued at $44,000. Hedge funds and other institutional investors own 4.67% of the company’s stock.

Check-Cap Company Profile (Get Rating)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Featured Stories